Niagen Bioscience, Inc.
NAGE
$3.65
-$0.15-3.95%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 20.84% | 29.95% | 36.04% | 35.89% | 29.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.84% | 29.95% | 36.04% | 35.89% | 29.77% |
| Cost of Revenue | 15.12% | 21.63% | 27.40% | 26.19% | 24.70% |
| Gross Profit | 24.27% | 35.08% | 41.47% | 42.15% | 33.01% |
| SG&A Expenses | 34.92% | 30.76% | 8.84% | 6.90% | -0.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.00% | 25.31% | 15.55% | 13.37% | 8.19% |
| Operating Income | -16.09% | 85.04% | 4,218.57% | 824.15% | 403.28% |
| Income Before Tax | 35.11% | 105.44% | 1,331.11% | 1,455.77% | 513.21% |
| Income Tax Expenses | 123.89% | 165.57% | -- | -- | -- |
| Earnings from Continuing Operations | 32.13% | 103.30% | 1,275.69% | 1,411.32% | 499.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.13% | 103.30% | 1,275.69% | 1,411.32% | 499.80% |
| EBIT | -16.09% | 85.04% | 4,218.57% | 824.15% | 403.28% |
| EBITDA | -14.56% | 76.59% | 1,458.93% | 1,354.64% | 513.99% |
| EPS Basic | 28.10% | 97.93% | 1,240.00% | 1,370.00% | 489.15% |
| Normalized Basic EPS | -13.89% | 78.33% | 1,304.13% | 1,407.08% | 500.34% |
| EPS Diluted | 26.65% | 108.42% | 2,312.24% | 997.39% | 414.77% |
| Normalized Diluted EPS | -15.59% | 74.63% | 1,241.53% | 1,328.32% | 478.31% |
| Average Basic Shares Outstanding | 3.80% | 3.99% | 3.94% | 3.00% | 1.97% |
| Average Diluted Shares Outstanding | 7.43% | 9.77% | 11.22% | 9.29% | 5.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |